ZYME · Zymeworks Inc. · Documents
$28.37
+0.15 (+0.53%)
At close · Oct 26
Return incl. dividend (before tax)
Market Cap
$1.99B
Shares
70.96M
Volume · Oct 26
833.97K
Avg daily vol (3M)
881.53K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| ARS | — | 2026-10-26 | 2025-12-31 | |
| DEFA14A | Zymeworks Inc.’s Annual Meeting will be held December 15, 2026, at 9:00 am PT virtually. Proposals cover director elections, executive compensation and advisory-vote frequency, the 2026 Employee Stock Purchase Plan, board declassification, and KPMG LLP ratification. | 2026-10-26 | — | |
| DEF 14A | Zymeworks will hold a virtual annual meeting on December 15, 2026, to vote on directors, executive compensation, employee stock purchases, board declassification and auditor ratification. | 2026-10-26 | 2026-12-15 | |
| 8-K | Zymeworks entered an exclusive global collaboration with Roche for ZW209, contingent on HSR Clearance, providing $55.0 million upfront, $40.0 million at Phase Ib initiation, up to $718 million in milestones and tiered high-single-digit to mid-teen royalties on annual net sales. | 2026-10-23 | 2026-10-22 | |
| PRE 14A | Zymeworks Inc. will hold a virtual meeting on December 15, 2026. Stockholders will elect Class II directors, approve the 2026 Employee Stock Purchase Plan, declassify the board, ratify KPMG, and vote on executive compensation and say-on-pay frequency. | 2026-10-16 | 2026-12-15 | |
| Investor Event Transcript | Zymeworks Inc. closed its acquisition of Theravance Biopharma, financed through a $350 million non-recourse note secured by UPELRI cash flows, and expects 2026 revenue of $278 million to $292 million and EBITDA of $114 million to $128 million. | 2026-09-28 | 2026-09-30 | |
| 8-K | — | 2026-09-23 | — | |
| Investor Event Transcript | — | 2026-09-14 | 2026-09-30 | |
| 8-K | — | 2026-08-25 | — | |
| 10-Q | — | 2026-08-06 | 2026-06-30 | |
| 8-K | — | 2026-08-06 | — | |
| Investor Event Transcript | — | 2026-06-30 | — | |
| 8-K | — | 2026-06-29 | 2026-06-28 | |
| Investor Event Transcript | — | 2026-06-03 | 2026-06-30 | |
| 8-K | — | 2026-05-14 | — | |
| 8-K | — | 2026-05-07 | — | |
| 10-Q | — | 2026-05-07 | 2026-03-31 | |
| Investor Event Transcript | — | 2026-04-21 | 2026-06-30 | |
| 8-K | — | 2026-04-01 | 2026-03-31 | |
| 10-K | — | 2026-03-02 | 2025-12-31 | |
| 8-K | — | 2026-03-02 | — | |
| 8-K | — | 2026-03-02 | — | |
| 8-K | — | 2026-01-12 | 2026-01-06 | |
| 8-K | — | 2025-12-30 | — | |
| 8-K | — | 2025-11-18 | 2025-11-16 | |
| 8-K | — | 2025-11-17 | — | |
| DEFA14A | — | 2025-11-10 | — | |
| DEF 14A | — | 2025-11-10 | 2025-12-30 | |
| ARS | — | 2025-11-10 | 2024-12-31 | |
| 8-K | — | 2025-11-06 | — | |
| 10-Q | — | 2025-11-06 | 2025-09-30 | |
| 8-K | — | 2025-09-02 | — | |
| 8-K | — | 2025-08-11 | 2025-08-09 | |
| 8-K | — | 2025-08-07 | — | |
| 10-Q | — | 2025-08-07 | 2025-06-30 | |
| 8-K | — | 2025-06-27 | 2025-06-26 | |
| 8-K | — | 2025-05-30 | — | |
| 8-K | — | 2025-05-08 | — | |
| 10-Q | — | 2025-05-08 | 2025-03-31 | |
| 10-K | — | 2025-03-05 | 2024-12-31 | |
| 8-K | — | 2025-03-05 | — | |
| 8-K | — | 2025-02-18 | 2025-02-17 | |
| 8-K | — | 2025-01-08 | — | |
| 8-K | — | 2024-12-11 | 2024-12-10 | |
| 8-K | — | 2024-11-21 | — | |
| 8-K | — | 2024-10-31 | — | |
| 10-Q | — | 2024-10-31 | 2024-09-30 | |
| ARS | — | 2024-10-29 | 2023-12-31 | |
| DEFA14A | — | 2024-10-29 | — | |
| DEF 14A | — | 2024-10-29 | 2024-12-10 |
Showing 1–50 of 121 filings
Key facts
CIK
1937653
CUSIP
98985Y108
13F (30d)
24 filings
24 filers
Visit website
Investor relations